However, a study indicated that the forced expiratory volume in 1 s (FEV1) level, incidence of asthma exacerbation, and quality of life in patients failed to benefit from treatment with the humanized IL-9 neutralizing antibody MEDI-528, also known as enoclizumab [24]. This evidence concerns the gene IL9 and asthma.